| Similar Articles |
|---|
 |
The Motley Fool
September 28, 2004
Brian Gorman |
Cambrex's Dose of Reality The biopharma's outlook is cloudy due to stiffer competition in biomanufacturing.   |
The Motley Fool
June 22, 2005
Brian Gorman |
Biotech's Global Agenda Bristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
Pharmaceutical Executive
June 1, 2005
Sibyl Shalo |
Chief of Staph Nabi, a small pharmaceutical company, has found a way to make money by making vaccines. Nabi now aims to become the first company to market a vaccine to attack the deadly staph bacterium. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
December 23, 2003
David Nierengarten |
An Undervalued Biotech Nabi Biopharmaceuticals has revenues and a pipeline. Is it undervalued? |
The Motley Fool
October 14, 2010
Matt Koppenheffer |
Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume. |
